GlassScriptPhysician profile
Stephen William Asher
NPI 1871523373
$9,746.20
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,518 · 2020: $233 · 2021: $995.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $5,461.39 | 2019 | |
| Boston Scientific Corporation | $1,444.93 | 2019 | |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Emd Serono, INC. | $287.10 | 2019 | |
| Supernus Pharmaceuticals, INC. | $155.94 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $153.54 | 2019 | |
| Alexion Pharmaceuticals, INC. | $143.03 | 2019 | |
| Lilly USA, LLC | $135.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.25 | 2019 | |
| Acorda Therapeutics, INC | $123.35 | 2019-2020 | |
| Kyowa Kirin, INC. | $113.40 | 2020 | |
| Medtronic USA, INC. | $110.74 | 2019 | |
| Insightec,INC | $83.58 | 2019 | |
| Abbvie INC. | $61.15 | 2021 | |
| Greenwich Biosciences, INC. | $46.31 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $44.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.18 | 2019 | |
| Genzyme Corporation | $36.70 | 2019-2020 | |
| Allergan, INC. | $34.53 | 2019-2020 | |
| Amgen INC. | $28.62 | 2019 | |
| Genentech USA, INC. | $28.26 | 2019-2020 | |
| Biogen, INC. | $27.29 | 2019 | |
| Acadia Pharmaceuticals INC | $25.67 | 2019 | |
| Livanova USA, INC. | $24.26 | 2020 | |
| Csl Behring | $21.03 | 2019 | |
| Lundbeck LLC | $20.17 | 2019 | |
| Celgene Corporation | $16.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.68 | 2021 | |
| Saol Therapeutics INC. | $15.22 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.